Clinical trial
A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
NCT02763579 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 7, 2016
- Completion date
- July 7, 2022
- Enrollment
- 503 (actual)
- Sites
- 114
Conditions
As the registry lists them; a condition with its own page is linked.